Transgene Biotek enters into agreement with NeoDeL Pharma

18 Mar 2021 Evaluate

Transgene Biotek has entered into an agreement with NeoDeL Pharma to support NeoDeL's Covid Vaccine project by formulating that company's Covid Vaccine, 'NeoCoVTM' for it to be administered in the form of oral and nasal drops. 

NeoDeL Pharma has entered into an agreement with a renowned university in USA which has developed a novel Covid vaccine. NeoDeL is to seek requisite regulatory approvals in India for NeoC0VTM to be manufactured and marketed globally. Transgene provides support to NeoDeL through its novel delivery platform by formulating NeoCoV for it to be administered either as oral or nasal drops, first of its kind in the world. Transgene is to receive compensation through a combination of milestone payments, equity and royalty on sales.

Transgene Biotek (TBL) is engaged in manufacturing drugs for:New Drug Delivery System (NDDS)-Oral Delivery of Insulin,Oral Delivery Hepatitis B Vaccine and Pegylation of Protein Drugs.

Transgene Biotek Share Price

7.07 0.14 (2.02%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7036.65
Max Healthcare Inst 1006.75
Narayana Hrudayalay 1249.35
Aster DM Healthcare 444.55
Global Health 1115.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.